New cell therapy aims to reset immune system in devastating autoimmune diseases

NCT ID NCT06947460

Summary

This study is testing a new cell therapy called CD19-BCMA CAR-T for people with severe autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy is safe and can help control diseases like lupus affecting the kidneys, systemic sclerosis, and Sjogren's syndrome with lung complications. The study will enroll about 45 participants to monitor side effects and see if their disease improves.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 北京高博医院

    RECRUITING

    Beijing, China,Beijing, 102200, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.